regenerative medicine
按立场 · 1 takes across the edition
The Regen Report · United States · Retro Biosciences raises at $1.8B as Alzheimer's trial advances
Frames the close around Sam Altman's involvement, ~$180M invested, a stake valued at ~$258M in May 2026 court filings, and Retro's positioning against Altos Labs in the cellular-rejuvenation race.
“Altman-Backed Regenerative Medicine Startup, Retro Biosciences, Closes Funding Round at $1.8B Valuation.”